| 1BYQ | A: | HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG |
| 1OSF | A: | HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY-17-N,N-DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN |
| 1UY6 | A: | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4,5-TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE |
| 1UY7 | A: | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4-METHOXY-BENZYL)-9H-PURIN-6-YLAMINE |
| 1UY8 | A: | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3-TRIMETHOXY-BENZYL)-9H-PURIN-6YLAMINE |
| 1UY9 | A: | HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-PURIN-6-YLAMINE |
| 1UYC | A: | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE |
| 1UYD | A: | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2-CHLORO-3,4,5-TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE |
| 1UYE | A: | HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5-TRIMETHOXY-BENZYL)-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE |
| 1UYF | A: | HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5-TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE |
| 1UYG | A: | HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE |
| 1UYH | A: | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY-BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE |
| 1UYI | A: | HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2-FLUORO-9-PENT-9H-PURIN-6-YLAMINE |
| 1UYK | A: | HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-2-FLUORO-9H-PURIN-6-YLAMINE |
| 1UYL | A: | STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE-BASED INHIBITOR BINDING TO HSP90 ISOFORMS |
| 1UYM | A: | HUMAN HSP90-BETA WITH PU3 (9-BUTYL-8(3,4,5-TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE) |
| 1YC1 | A: | CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED WITH DIHYDROXYPHENYLPYRAZOLES |
| 1YC3 | A: | CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED WITH DIHYDROXYPHENYLPYRAZOLES |
| 1YC4 | A: | CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED WITH DIHYDROXYPHENYLPYRAZOLES |
| 1YER | A: | HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" CONFORMATION |
| 1YES | A: | HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" CONFORMATION |
| 1YET | A: | GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING DOMAIN |
| 2FWY | A: | STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATER SOLUBLE INHIBITOR PU-H64 |
| 2FWZ | A: | STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATER SOLUBLE INHIBITOR PU-H71 |
| 2H55 | A: | STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATER SOLUBLE INHIBITOR PU-DZ8 |
| 2QF6 | A:17-223; B:17-223; C:17-223; D:17-223 | HSP90 COMPLEXED WITH A56322 |
| 2QFO | A:; B: | HSP90 COMPLEXED WITH A143571 AND A516383 |
| 2QG0 | A:; B: | HSP90 COMPLEXED WITH A943037 |
| 2QG2 | A: | HSP90 COMPLEXED WITH A917985 |
| 2YJW | A: | TRICYCLIC SERIES OF HSP90 INHIBITORS |
| 2YJX | A: | TRICYCLIC SERIES OF HSP90 INHIBITORS |
| 2YK2 | A: | TRICYCLIC SERIES OF HSP90 INHIBITORS |
| 2YK9 | A: | TRICYCLIC SERIES OF HSP90 INHIBITORS |
| 2YKB | A: | TRICYCLIC SERIES OF HSP90 INHIBITORS |
| 2YKC | A: | TRICYCLIC SERIES OF HSP90 INHIBITORS |
| 2YKE | A: | TRICYCLIC SERIES OF HSP90 INHIBITORS |
| 2YKI | A: | TRICYCLIC SERIES OF HSP90 INHIBITORS |
| 2YKJ | A: | TRICYCLIC SERIES OF HSP90 INHIBITORS |
| 3BM9 | A: | DISCOVERY OF BENZISOXAZOLES AS POTENT INHIBITORS OF CHAPERONE HSP90 |
| 3BMY | A: | DISCOVERY OF BENZISOXAZOLES AS POTENT INHIBITORS OF CHAPERONE HSP90 |
| 3EKO | A:; B: | DIHYDROXYLPHENYL AMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE |
| 3EKR | A:; B: | DIHYDROXYLPHENYL AMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE |
| 3FT5 | A: | STRUCTURE OF HSP90 BOUND WITH A NOVEL FRAGMENT |
| 3FT8 | A: | STRUCTURE OF HSP90 BOUND WITH A NOVAL FRAGMENT. |
| 3INW | A: | HSP90 N-TERMINAL DOMAIN WITH POCHOXIME A |
| 3INX | A: | HSP90 N-TERMINAL DOMAIN WITH POCHOXIME B |
| 3K98 | A:; B: | HSP90 N-TERMINAL DOMAIN IN COMPLEX WITH (1R)-2-(5-CHLORO-2, 4-DIHYDROXYBENZOYL)-N-ETHYLISOINDOLINE-1-CARBOXAMIDE |
| 3K99 | A:; B:; C:; D: | HSP90 N-TERMINAL DOMAIN IN COMPLEX WITH 4-(1,3-DIHYDRO-2H-ISOINDOL-2-YLCARBONYL)BENZENE-1,3-DIOL |
| 3OW6 | A: | CRYSTAL STRUCTURE OF HSP90 WITH N-ARYL-BENZIMIDAZOLONE I |
| 3OWB | A: | CRYSTAL STRUCTURE OF HSP90 WITH VER-49009 |
| 3OWD | A: | CRYSTAL STRUCTURE OF HSP90 WITH N-ARYL-BENZIMIDAZOLONE II |
| 3QDD | A: | HSP90A N-TERMINAL DOMAIN IN COMPLEX WITH BIIB021 |
| 3R4M | A: | OPTIMIZATION OF POTENT, SELECTIVE, AND ORALLY BIOAVAILABLE PYRROLODINOPYRIMIDINE-CONTAINING INHIBITORS OF HEAT SHOCK PROTEIN 90. IDENTIFICATION OF DEVELOPMENT CANDIDATE 2-AMINO-4-{4-CHLORO-2-[2-(4-FLUORO-1H-PYRAZOL-1-YL)ETHOXY]-6-METHYLPHENYL}-N-(2,2-DIFLUOROPROPYL)-5,7-DIHYDRO-6H-PYRROLO[3,4-D]PYRIMIDINE-6-CARBOXAMIDE |
| 3R4N | A:; B: | OPTIMIZATION OF POTENT, SELECTIVE, AND ORALLY BIOAVAILABLE PYRROLODINOPYRIMIDINE-CONTAINING INHIBITORS OF HEAT SHOCK PROTEIN 90. IDENTIFICATION OF DEVELOPMENT CANDIDATE 2-AMINO-4-{4-CHLORO-2-[2-(4-FLUORO-1H-PYRAZOL-1-YL)ETHOXY]-6-METHYLPHENYL}-N-(2,2-DIFLUOROPROPYL)-5,7-DIHYDRO-6H-PYRROLO[3,4-D]PYRIMIDINE-6-CARBOXAMIDE |
| 3R4O | A:; B: | OPTIMIZATION OF POTENT, SELECTIVE, AND ORALLY BIOAVAILABLE PYRROLODINOPYRIMIDINE-CONTAINING INHIBITORS OF HEAT SHOCK PROTEIN 90. IDENTIFICATION OF DEVELOPMENT CANDIDATE 2-AMINO-4-{4-CHLORO-2-[2-(4-FLUORO-1H-PYRAZOL-1-YL)ETHOXY]-6-METHYLPHENYL}-N-(2,2-DIFLUOROPROPYL)-5,7-DIHYDRO-6H-PYRROLO[3,4-D]PYRIMIDINE-6-CARBOXAMIDE |
| 3R4P | A:; B: | OPTIMIZATION OF POTENT, SELECTIVE, AND ORALLY BIOAVAILABLE PYRROLODINOPYRIMIDINE-CONTAINING INHIBITORS OF HEAT SHOCK PROTEIN 90. IDENTIFICATION OF DEVELOPMENT CANDIDATE 2-AMINO-4-{4-CHLORO-2-[2-(4-FLUORO-1H-PYRAZOL-1-YL)ETHOXY]-6-METHYLPHENYL}-N-(2,2-DIFLUOROPROPYL)-5,7-DIHYDRO-6H-PYRROLO[3,4-D]PYRIMIDINE-6-CARBOXAMIDE |
| 3RLP | A:; B: | CO-CRYSTAL STRUCTURE OF THE HSP90 ATP BINDING DOMAIN IN COMPLEX WITH 4-(2,4-DICHLORO-5-METHOXYPHENYL)-6-METHYLPYRIMIDIN-2-AMINE |
| 3RLQ | A:; B: | CO-CRYSTAL STRUCTURE OF THE HSP90 ATP BINDING DOMAIN IN COMPLEX WITH 4-(2,4-DICHLORO-5-METHOXYPHENYL)-2-METHYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5- CARBONITRILE |
| 3RLR | A:; B: | CO-CRYSTAL STRUCTURE OF THE HSP90 ATP BINDING DOMAIN IN COMPLEX WITH 4-(2,4-DICHLORO-5-METHOXYPHENYL)-2,6-DIMETHYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBONITRILE |
| 3TUH | A:; B: | CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAIN OF AN HSP90 IN THE PRESENCE OF AN THE INHIBITOR GANETESPIB |
| 4EGH | A: | HSP90-ALPHA ATPASE DOMAIN IN COMPLEX WITH (4-HYDROXYPHENYL)MORPHOLIN-4-YL METHANONE |
| 4EGI | A: | HSP90-ALPHA ATPASE DOMAIN IN COMPLEX WITH 2-AMINO-4-ETHYLTHIO-6-METHYL-1,3,5-TRIAZINE |
| 4EGK | A: | HUMAN HSP90-ALPHA ATPASE DOMAIN BOUND TO RADICICOL |
| 4FCP | A:; B: | TARGETTING CONSERVED WATER MOLECULES: DESIGN OF 4-ARYL-5-CYANOPYRROLO [2,3-D] PYRIMIDINE HSP90 INHIBITORS USING FRAGMENT-BASED SCREENING AND STRUCTURE-BASED OPTIMIZATION |
| 4FCQ | A: | TARGETING CONSERVED WATER MOLECULES: DESIGN OF 4-ARYL-5-CYANOPYRROLO[2,3-D]PYRIMIDINE HSP90 INHIBITORS USING FRAGMENT-BASED SCREENING AND STRUCTURE-BASED OPTIMIZATION |
| 4FCR | A: | TARGETING CONSERVED WATER MOLECULES: DESIGN OF 4-ARYL-5-CYANOPYRROLO[2,3-D]PYRIMIDINE HSP90 INHIBITORS USING FRAGMENT-BASED SCREENING AND STRUCTURE-BASED OPTIMIZATION |
| 4JQL | A: | SYNTHESIS OF BENZOQUINONE-ANSAMYCIN-INSPIRED MACROCYCLIC LACTAMS FROM SHIKIMIC ACID |
| 4NH7 | A:; B: | CORRELATION BETWEEN CHEMOTYPE-DEPENDENT BINDING CONFORMATIONS OF HSP90 ALPHA/BETA AND ISOFORM SELECTIVITY |
| 4NH8 | A: | CORRELATION BETWEEN CHEMOTYPE-DEPENDENT BINDING CONFORMATIONS OF HSP90 ALPHA/BETA AND ISOFORM SELECTIVITY |
| 4O05 | A: | IDENTIFICATION OF NOVEL HSP90/ISOFORM SELECTIVE INHIBITORS USING STRUCTURE-BASED DRUG DESIGN. DEMONSTRATION OF POTENTIAL UTILITY IN TREATING CNS DISORDERS SUCH AS HUNTINGTON'S DISEASE |
| 4O07 | A: | IDENTIFICATION OF NOVEL HSP90/ISOFORM SELECTIVE INHIBITORS USING STRUCTURE-BASED DRUG DESIGN. DEMONSTRATION OF POTENTIAL UTILITY IN TREATING CNS DISORDERS SUCH AS HUNTINGTON'S DISEASE |
| 4O09 | A: | IDENTIFICATION OF NOVEL HSP90 / ISOFORM SELECTIVE INHIBITORS USING STRUCTURE-BASED DRUG DESIGN. DEMONSTRATION OF POTENTIAL UTILITY IN TREATING CNS DISORDERS SUCH AS HUNTINGTON S DISEASE |
| 4O0B | A: | IDENTIFICATION OF NOVEL HSP90/ISOFORM SELECTIVE INHIBITORS USING STRUCTURE-BASED DRUG DESIGN. DEMONSTRATION OF POTENTIAL UTILITY IN TREATING CNS DISORDERS SUCH AS HUNTINGTON'S DISEASE |
)
)